(Reuters) -The U.S. Food and Drug Administration has approved Elanco Animal Health's ( ELAN ) skin disease treatment for dogs, the health regulator's website showed on Thursday.

The oral drug, Zenrelia, is to control pruritus, or itching, associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.

Zenrelia, an immunosuppressant,is administered once daily, with or without food.

Shares of the company rose 3% in afternoon trade.

The company did not immediately respond to Reuters' request for pricing and availability.

The label of the drug recommends it should have a 28-day to 3-month washout period before any vaccination, and should not be administered for at least 28 days afterwards.

Zenrelia belongs to a class of drugs known as JAK inhibitors, which block inflammation-causing enzymes known as Janus kinases.